EGFR and cancer: Among these pathways, constitutive activation of the MAPK signaling pathway is a major cause of resistance to anti-EGFR therapies in KRAS- and BRAF-mutated cancers [192]. Finally, targeting multiple proteins in critical signaling pathways appears to be a promising concept for RAS-mutated patients [108] (Fig. 6).